Mankind Pharma Limited

MANKIND

INE634S01028

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:31 2024-07-09 am EDT			5-day change	1st Jan Change
2,102 ^INR	+1.95%		-1.25%	+6.05%

Jul. 09	Mankind Pharma Reportedly to See Stake Sale Worth INR 7,630 Million through Block Deal	CI
Jul. 05	Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	RE

Mankind Pharma Limited Announces Re-Designation of Mr. Suresh Raju Penmetsa as Chief Risk Officer

August 02, 2023 at 09:13 am EDT

Mankind Pharma Limited announced that Board of Directors of the Company at its meeting held on August 2, 2023, approved re-designation of Mr. Suresh Raju Penmetsa, Vice President - EHS (being Senior Management Personnel) as "Chief Risk Officer and Vice President- EHS", effective August 2, 2023 as recommended by Nomination and Remuneration Committee.

Latest news about Mankind Pharma Limited

Mankind Pharma Reportedly to See Stake Sale Worth INR 7,630 Million through Block Deal	Jul. 09	CI
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids	Jul. 05	RE
Mankind Pharma Limited Receives Order from Office of Superintendent of Central Tax, Bholakpur, Telangana	Jun. 03	CI
Advent International Receives 6-7 Bids for Bharat Serums	May. 30	CI
Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024	May. 16
Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4	May. 16	MT
India's Mankind Pharma's Q4 profit jumps on strength in chronic drugs segment	May. 15	RE
Mankind Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 15	CI
India's weight in key MSCI equity index hits another high, to boost inflows	May. 14	RE
Mankind Pharma Reportedly in Fray to Acquire Advent's Stake in Bharat Serums	May. 14	CI
Mankind Pharma Limited Receives Order from Office of the Assistant Commissioner of Central Tax, Ballygunge Division Kolkata	May. 09	CI
KKR, Novo Nordisk, Others Reportedly Bid for Healthium Buy	May. 02	CI
Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad	Apr. 26	CI
CARE Gives AA+ Rating to Mankind Pharma's Long-term Bank Financing; Outlook Stable	Apr. 26	MT
Mankind Pharma to Sell its Over the Counter Business on Slump Sale Basis	Apr. 03	CI
Mankind Pharma to Sell OTC Business to Wholly-Owned Subsidiary	Apr. 03	MT
Mankind Pharma to Form New Subsidiary for Consumer Healthcare Products	Apr. 02	MT
Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary Mankind Consumer Products Private Limited	Apr. 02	CI
Mankind Reportedly Joins Race for Healthium Medtech	Mar. 28	CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	Mar. 11	MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	Mar. 11	CI
India's Jubilant Pharmova posts quarterly profit	Feb. 02	RE
Transcript : Mankind Pharma Limited, Q3 2024 Earnings Call, Feb 02, 2024	Feb. 02
Mankind Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit; Shares Rise 3%	Feb. 01	MT
India's Mankind Pharma beats Q3 profit estimates on strong demand	Jan. 31	RE

Chart Mankind Pharma Limited

Duration

Period

More charts

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mankind Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,102 INR

Average target price

2,303 INR

Spread / Average Target

+9.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MANKIND PHARMA LIMITED	+6.05%	9.9B
ELI LILLY AND COMPANY	+59.97%	827B
NOVO NORDISK A/S	+38.38%	634B
JOHNSON & JOHNSON	-6.18%	350B
MERCK & CO., INC.	+15.61%	319B
ABBVIE INC.	+8.44%	294B
ASTRAZENECA PLC	+12.68%	240B
NOVARTIS AG	+14.40%	221B
ROCHE HOLDING AG	+0.04%	219B
AMGEN INC.	+9.68%	167B

Other Pharmaceuticals